Navigation Links
PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant
Date:7/31/2008

DuraClean(TM) to Launch in Multiple Markets, Including Industrial

Contracted Services

SAN DIEGO, July 31 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) today announced an agreement with DuraBan International Inc for distribution of PURE's silver dihydrogen citrate (SDC)-based disinfectant under DuraBan's DuraClean(TM) brand.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)

DuraBan International Inc, a Minneapolis based chemical manufacturer specializing in earth-friendly antimicrobial technologies, intends to sell DuraClean through its existing distribution channels into multiple markets, including the building, consumer products, medical, service and industrial sectors.

Robert Dahl, founder of DuraBan, commented, "DuraBan's foundation has been built on providing earth-friendly antimicrobial solutions, of which SDC powered DuraClean is a perfect example. We expect it to provide an attractive, effective and efficient solution for our customers, as DuraBan stays true to its heritage of providing safe, effective and efficient solutions to our customers in the worldwide consumer, industrial and medical marketplace."

Michael L. Krall, President and CEO of PURE Bioscience, stated, "SDC is a perfect complement for DuraBan's product line, which features safe and green antimicrobial barrier technologies. DuraClean will be marketed through DuraBan's established distribution channels. These channels include a wide variety of markets, some of which will be significant new entry points for our SDC-based disinfectant, such as the industrial contracted services area."

DuraBan has registered DuraClean with the US EPA as a sub-registrant of PURE Bioscience and is currently undergoing registration in all 50 states. In accordance with the agreement, each bottle of DuraClean features PURE's "Powered by SDC" logo. The contract also provides for increasing annual minimum purchases; other specific terms of the contract were not disclosed.

DuraClean disinfectant carries a 30 second kill time on standard indicator bacteria, a 24 hour residual kill on standard indicator bacteria, a 2 minute kill time on some resistant strains of bacteria, 10 minute kill time on fungi, 30 second kill time on HIV Type I, and 10 minute kill time on other pathogenic viruses. These claims distinguish the efficacy of DuraClean from many of the leading commercial and consumer products currently on the market, while maintaining lower toxicity ratings. Based on the EPA toxicity ratings from Category I (high toxicity) down to Category IV, DuraClean is a Category IV antimicrobial for which precautionary labeling statements are not required. This compares with Category II warning statements for most leading brands of disinfectant products.

About DuraBan

DuraBan International Inc, is a Minneapolis, Minn., based chemical manufacturer and emerging global innovator of built-in, earth-friendly, antimicrobial product protection. DuraBan engineers safe and durable antimicrobial solutions for consumer, industrial and medical products around the world. Its technology can be engineered into a variety of surfaces and materials including: coatings, polymers, textiles, lumber, plastic and adhesives. Built-in to products during the manufacturing process, DuraBan antimicrobial product protection inhibits the growth of microbes, such as bacteria, mold and mildew that can cause stains, odors and product deterioration. DuraBan's proprietary and patented antimicrobial technologies deliver unmatched performance, durability and efficacy through a unique formulation based on surface-modifying nanotechnology. Once applied, DuraBan chemically bonds to the product surface, creating a permanent antimicrobial barrier that destroys microorganisms upon contact. DuraBan's antimicrobial has never been shown to allow or cause microbial adaptation, resistance, mutation, diffusion, or migration and easily bonds to almost any surface, creating unlimited applications for this breakthrough technology. For more information, please visit http://www.durabanintl.com.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at http://www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

PURE Bioscience Investor Contact:

Paul G. Henning, Vice President

Cameron Associates

(212) 554-5462

paul@cameronassoc.com


'/>"/>
SOURCE PURE Bioscience
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... ... President for Public Policy for the National Organization for Rare Disorders (NORD). Dorman ... to ensure their voices are heard throughout the drug regulatory review process. , ...
(Date:2/9/2016)... This market research report on the global ... of the market in terms of revenue (USD Million). ... the manufacture of microbiology culture media and related products. ... snapshot providing the overall information of various market segments ... also provides the overall information and data analysis of ...
(Date:2/9/2016)... LEXINGTON, Massachusetts , February 9, 2016 ... Enables Children to Take Part in Life-Changing Camp ... announcing a new initiative designed to positively affect the lives of ... rare disease care. --> SHPG ) is announcing a ... with rare diseases, as well as the future of rare disease ...
(Date:2/9/2016)... , Feb. 9, 2016 ... Insights, 2016", report provides in depth insights ... activities around the Protein-Tyrosine Phosphatase 1B (PTP1B) ... profiles in various stages of development including ... Phase III and Preregistration. Report covers the ...
Breaking Biology Technology:
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/20/2016)... , Jan. 20, 2016 A market ... to directly benefit from the explosion in genomics knowledge. ... Howe Sound Research. A range of dynamic trends are ... - personalized medicine - pharmacogenomics - pathogen evolution ... with large markets - greater understanding of the role ...
(Date:1/15/2016)... 2016 Recent publicized breaches in cyber security ... ways to ensure data security and user authentication in ... Android that ties a user,s mobile number ... a hardware authorization token. Customer service agents who employ ... their KodeKey enabled device to verify their identity.  Companies ...
Breaking Biology News(10 mins):